Inhibitors of TRPC6 for treating focal segmental glomerulosclerosis
TRPC6 inhibitors, such as compounds of formula (I), offer a novel approach to treating FSGS by reducing proteinuria and preserving renal function, addressing the challenges of limited therapeutic options for this disease.
WO2025042707A1 Publication Date: 2025-02-27BOEHRINGER INGELHEIM INT GMBH
4 Cites 0 Cited by
Patent Information
- Application Number
- PCT/US2024/042613
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-08-18
- Filing Date
- 2024-08-16
- Publication Date
- 2025-02-27
AI Technical Summary
Technical Problem
Focal segmental glomerulosclerosis (FSGS) is a leading cause of End Stage Kidney Disease (ESKD) with limited effective therapeutic interventions, and increased TRPC6 activity is hypothesized to be a key mechanism driving proteinuric kidney disease and progression to ESKD.
Method used
Administration of a pharmaceutically effective amount of a TRPC6 inhibitor, specifically compounds of formula (I) or their pharmaceutically acceptable salts, to reduce proteinuria and preserve renal function in patients with FSGS.
Benefits of technology
The use of TRPC6 inhibitors is expected to reduce proteinuria and preserve renal function in FSGS patients, potentially slowing or halting the progression to ESKD by modulating podocyte function and survival.
✦ Generated by Eureka AI based on patent content.
Abstract
Disclosed are methods for treating focal segmental glomerulosclerosis (FSGS), comprising administering to a patient in need thereof a pharmaceutically effective amount of a compound of formula (I), wherein R1 to R7, A, L and Y are as defined herein. Also disclosed are pharmaceutical compositions comprising the compound of formula (I) and their use for treating FSGS.
Need to check novelty before this filing date? Find Prior Art
